Earnings calls

Beta Drugs Ltd concall ledger

Every earnings call for BETA — management tone, guidance, KPIs and promise tracking, quarter by quarter.

BETA · 3 transcripts · Healthcare · latest Q4 FY26

Beta Drugs Ltd has 3 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.

Q4 FY26Published 15 May 2026Call held 15 May 2026

BETA Q4 FY26 Earnings Call Transcript & Analysis

EBITDA₹86.85 cr+13% YoYEBITDA Margin22.57%+7% YoYGross Margin55.52%+5% YoY

EBITDA ₹87 cr (+13% YoY); EBITDA Margin 22.57% (+7% YoY); Gross Margin 55.52% (+5% YoY). Net revenue grew to INR396 crores, up 7.6% YoY.

Read full transcript & analysis

Q2 FY26Published 07 Nov 2025Call held 07 Nov 2025

BETA Q2 FY26 Earnings Call Transcript & Analysis

EBITDA₹47 cr+17% YoYEBITDA Margin23.08%+3% YoYPAT₹28.71 cr+18% YoYPAT Margin14.1%+4% YoY

EBITDA ₹47 cr (+17% YoY); EBITDA Margin 23.08% (+3% YoY); PAT (excl. debenture interest) ₹29 cr (+18% YoY). Revenue of ₹204 crores, up 13% YoY.

Read full transcript & analysis

Q4 FY25Published 16 May 2025Call held 16 May 2025

BETA Q4 FY25 Earnings Call Transcript & Analysis

Consolidated Revenue₹362.35 cr+23% YoYConsolidated EBITDA₹81.04 cr+32% YoYEBITDA Margin22.37%Net Profit₹45.83 cr+26% YoY

Consolidated Revenue ₹362 cr (+22% YoY); Consolidated EBITDA ₹81 cr (+32% YoY); EBITDA Margin 22.37%. Consolidated revenue grew 22.5% YoY to ₹362.35 crores.

Read full transcript & analysis